Corgenix Medical Corp.’s ReEBOV antigenassay is the first rapid test and immunoassay for the Ebola virus granted an emergency use authorization
by FDA. The test was also recently selected by the World Health Organization for its diagnostics procurement listing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?